Outcome Prediction for Estrogen Receptor-Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics

2008653 citationsJournal Articlehybrid Open Access

Authors

Michael J. Ellis · Institute of Cancer Research

Yu Tao · Royal Marsden Hospital

Jingqin Luo · German Red Cross

Roger A’Hern · German Red Cross

Dean B. Evans · Royal Marsden Hospital

A.S. Bhatnagar · Washington University in St. Louis

Hilary A. Chaudri Ross ·

Abstract

Breast cancer patients with pathological stage 1 or 0 disease after neoadjuvant endocrine therapy and a low-risk biomarker profile in the surgical specimen (PEPI score 0) have an extremely low risk of relapse and are therefore unlikely to benefit from adjuvant chemotherapy.

Topics & Keywords

Breast Cancer Treatment Studies Estrogen and related hormone effects HER2/EGFR in Cancer Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: JNCI Journal of the National Cancer Institute

Volume 100, Issue 19, pp. 1380-1388

DOI: 10.1093/jnci/djn309

Field-Weighted Citation Impact: 16.41